Morgan Stanley
NEUP

Morgan Stanley’s Neuphoria Therapeutics NEUP Stock Holding History

Morgan Stanley’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$236 Hold
58
– – ﹤0.01% 7684
2025
Q4 		$225 Buy
58
+51
+729% +$362 ﹤0.01% 7612
2025
Q3 		$83 Hold
7
– – ﹤0.01% 7720
2025
Q2 		$50 Hold
7
– – ﹤0.01% 7789
2025
Q1 		$40 Hold
7
– – ﹤0.01% 7801
2024
Q4 		$24 Sell
7
-68
-91% -$240 ﹤0.01% 7839
2024
Q3 		$393 Buy
75
+9
+14% +$71 ﹤0.01% 7323
2024
Q2 		$609 Buy
66
+58
+725% +$632 ﹤0.01% 7209
2024
Q1 		$97 Sell
8
-15,820
-100% -$209K ﹤0.01% 7379
2023
Q4 		$281K Buy
+15,828
New +$452K ﹤0.01% 5820

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Morgan Stanley's NEUP Position: Q1 2026 in Review

Morgan Stanley held its Neuphoria Therapeutics (NEUP) position steady in Q1 2026 at 58 shares worth $236. The position accounts for ﹤0.01% of the portfolio, ranked #7684.

Morgan Stanley first reported a position in NEUP in Q4 2023 and has held it in 10 quarters since. The position peaked at $281K in Q4 2023. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Morgan Stanley held 58 shares of Neuphoria Therapeutics worth $236 as of Q1 2026.
  • Morgan Stanley left its Neuphoria Therapeutics share count unchanged in Q1 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7684 holding.
  • Morgan Stanley first reported a position in Neuphoria Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Morgan Stanley's Neuphoria Therapeutics position peaked at $281K in Q4 2023.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.